Abstract
MARK3 (microtubule affinity regulating kinase 3) is a serine/threonine protein kinase. The protein kinases have a regulatory role in cell biology, involved in a variety of cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. Deregulation of these protein kinases triggers a variety of diseases such as cancer, diabetes, cardiovascular and nervous system disorders, which highlights this family of proteins as druggable targets. However, the development of competitive inhibitors to protein kinases is a challenging task due to the high level of similarity between members of this family, ranging from 50 to 85 % of sequence identity. The structure-based techniques were performed to design novel MARK3 inhibitors. Structure-based virtual screening experiments were performed selecting 20 compounds whose activity profiles were predicted using PASS and DEREK softwares. In addition, the top docking solutions were evaluated by molecular dynamics simulations.
Keywords: Cancer, MARK3, structure-based virtual screening.
Current Bioactive Compounds
Title:Structure-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Volume: 10 Issue: 2
Author(s): Josiana G. de Araujo Volpini, Ricardo P. Rodrigues, Leonardo B. Federico and Carlos H.T. de Paula da Silva
Affiliation:
Keywords: Cancer, MARK3, structure-based virtual screening.
Abstract: MARK3 (microtubule affinity regulating kinase 3) is a serine/threonine protein kinase. The protein kinases have a regulatory role in cell biology, involved in a variety of cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. Deregulation of these protein kinases triggers a variety of diseases such as cancer, diabetes, cardiovascular and nervous system disorders, which highlights this family of proteins as druggable targets. However, the development of competitive inhibitors to protein kinases is a challenging task due to the high level of similarity between members of this family, ranging from 50 to 85 % of sequence identity. The structure-based techniques were performed to design novel MARK3 inhibitors. Structure-based virtual screening experiments were performed selecting 20 compounds whose activity profiles were predicted using PASS and DEREK softwares. In addition, the top docking solutions were evaluated by molecular dynamics simulations.
Export Options
About this article
Cite this article as:
de Araujo Volpini Josiana G., P. Rodrigues Ricardo, B. Federico Leonardo and de Paula da Silva Carlos H.T., Structure-Based Drug Design of Novel MARK-3 Inhibitors in Cancer, Current Bioactive Compounds 2014; 10 (2) . https://dx.doi.org/10.2174/157340721002141001103308
DOI https://dx.doi.org/10.2174/157340721002141001103308 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
Anti-Cancer Agents in Medicinal Chemistry Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Potential Role of Biological Systems in Formation of Nanoparticles: Mechanism of Synthesis and Biomedical Applications
Current Nanoscience Formulation Development of Chitosan Coated Intra Nasal Ropinirole Nanoemulsion for Better Management Option of Parkinson: An In Vitro Ex Vivo Evaluation
Current Nanoscience Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Micro-CT Assessments of Potential Anti-Osteoporotic Agents
Current Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors
Combinatorial Chemistry & High Throughput Screening Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Serum HSP90-Alpha and Oral Squamous Cell Carcinoma: A Prospective Biomarker
Protein & Peptide Letters Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry